Clinical Trials Browser

Phase 2 × pidilizumab × Dermatologic × Clear all

NCT01435369 2016-01-21

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma